

# Market Announcement

20 April 2020

---

## Cardiex Limited (ASX: CDX) – Trading Halt

### Description

The securities of Cardiex Limited ('CDX') will be placed in trading halt at the request of CDX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 22 April 2020 or when the announcement is released to the market.

### Issued by

**Corey Lian**

Adviser, Listings Compliance (Sydney)



20 April 2020

Mr Corey Lian

By Email

To: [Corey.Lian@asx.com.au](mailto:Corey.Lian@asx.com.au) ; [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

---

Dear Sir,

**RE: Request for Trading Halt on Securities of CardieX Limited  
(ASX: CDX)**

Pursuant to Listing Rule 17.1, pending an announcement regarding a material development in its development of a sensor for its joint development agreement Mobvoi, CDX formally applies for a trading halt to be put in place immediately.

That trading halt is requested to be in place until commencement of trade 22 April 2020 or when that announcement is released to the market.

CDX is not aware of any reason why the Company's request for a trading halt should not be granted.

Yours sincerely,

**CARDIEX LIMITED**

A handwritten signature in blue ink, appearing to read "Jarrod White", written over the company name.

**JARROD WHITE  
CHIEF FINANCIAL OFFICER | COMPANY SECRETARY**

For more information please contact:

Chief Financial Officer  
Jarrod White  
Ph: +61 8296 0000  
[jwhite@cardiex.com](mailto:jwhite@cardiex.com)

Investor Relations  
Peter Taylor  
Ph: +61 412 036 231  
[peter@nwrcommunications.com.au](mailto:peter@nwrcommunications.com.au)

**Cardiex**

CardieX Limited is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. CardieX also has a 50/50 joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with telehealth services provider, inHealth Medical Services, Inc, allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.